Literature DB >> 18057009

Nuclear survivin has reduced stability and is not cytoprotective.

Claire M Connell1, Rita Colnaghi1, Sally P Wheatley2.   

Abstract

Survivin is an essential mitotic protein that is overexpressed in many cancers, and its presence is correlated with increased resistance to radiation and chemotherapy. Here we demonstrate that sending survivin into the nucleus accelerates its degradation in a cdh1-dependent manner, abolishes the radio resistance normally conferred to cells by its overexpression, and prevents survivin from inhibiting apoptosis without affecting its mitotic localization. Our data suggest that targeting survivin to the nucleus provides an efficient means of eliminating it from the cell and may prove a novel strategy in cancer treatment, particularly in combination with radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18057009     DOI: 10.1074/jbc.M704461200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

Review 1.  Survivin at a glance.

Authors:  Sally P Wheatley; Dario C Altieri
Journal:  J Cell Sci       Date:  2019-04-04       Impact factor: 5.285

2.  The role of survivin in diagnosis, prognosis and treatment of breast cancer.

Authors:  Yong-Gang Lv; Fang Yu; Qing Yao; Jiang-Hao Chen; Ling Wang
Journal:  J Thorac Dis       Date:  2010-06       Impact factor: 2.895

3.  TP53 Mutational Status and ROS Effect the Expression of the Survivin-Associated Radio-Adaptive Response.

Authors:  Jeffrey S Murley; Richard C Miller; Ralph R Weichselbaum; David J Grdina
Journal:  Radiat Res       Date:  2017-08-16       Impact factor: 2.841

4.  Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder.

Authors:  Deepika Dhawan; Bruce A Craig; Liang Cheng; Paul W Snyder; Sulma I Mohammed; Jane C Stewart; Rong Zheng; Rhoda A Loman; Richard S Foster; Deborah W Knapp
Journal:  Mol Cancer Ther       Date:  2010-04-27       Impact factor: 6.261

5.  Differentially localized survivin and STAT3 as markers of gastric cancer progression: Association with Helicobacter pylori.

Authors:  Arvind Pandey; Satyendra Chandra Tripathi; Shirish Shukla; Sutapa Mahata; Kanchan Vishnoi; Sri Prakash Misra; Vatsala Misra; Sankar Mitra; Manisha Dwivedi; Alok C Bharti
Journal:  Cancer Rep (Hoboken)       Date:  2018-06-01

6.  Survivin is a key factor in the differential susceptibility of gastric endothelial and epithelial cells to alcohol-induced injury.

Authors:  M K Jones; O R Padilla; E Zhu
Journal:  J Physiol Pharmacol       Date:  2010-06       Impact factor: 3.011

7.  Survivin expression in lung cancer: Association with smoking, histological types and pathological stages.

Authors:  Hiroshi Hirano; Hajime Maeda; Toshihiko Yamaguchi; Soichiro Yokota; Masahide Mori; Saburo Sakoda
Journal:  Oncol Lett       Date:  2015-06-16       Impact factor: 2.967

8.  Threonine 48 in the BIR domain of survivin is critical to its mitotic and anti-apoptotic activities and can be phosphorylated by CK2 in vitro.

Authors:  Rachel M A Barrett; Rita Colnaghi; Sally P Wheatley
Journal:  Cell Cycle       Date:  2011-02-01       Impact factor: 4.534

9.  Glycogen synthase kinase 3beta induces apoptosis in cancer cells through increase of survivin nuclear localization.

Authors:  Jiansha Li; Mingyou Xing; Min Zhu; Xi Wang; Manxiang Wang; Sheng Zhou; Naping Li; Renliang Wu; Muxiang Zhou
Journal:  Cancer Lett       Date:  2008-08-12       Impact factor: 8.679

Review 10.  New wirings in the survivin networks.

Authors:  D C Altieri
Journal:  Oncogene       Date:  2008-10-20       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.